Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide LAR in severe polycystic liver disease
NCT00426153Phase 3Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2007
- Primary completion
- Oct 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of Octreotide long-acting injection in Polycystic liver disease (PLD), sponsored by Mayo Clinic. Started Jan 2007; status: completed.
02
Drugs
Octreotide long-acting injection
03
Conditions
Polycystic liver disease (PLD)
Beyond the preview
Go deeper on NCT00426153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00426153.